R18.0 Malignant ascites

Name of the Condition

• Malignant Ascites

Summary

Malignant ascites is the accumulation of fluid in the peritoneal cavity due to cancer. It is a common complication in advanced malignancies, particularly those affecting the abdomen or pelvis. The condition results from increased fluid production, impaired absorption, or lymphatic obstruction caused by tumor infiltration. Malignant ascites can cause significant abdominal distension, discomfort, and impaired organ function.

Causes

Malignant ascites develops when cancer cells invade the peritoneum or obstruct lymphatic drainage, leading to fluid buildup. Common primary cancers associated with this condition include ovarian, pancreatic, gastric, colorectal, and liver malignancies. Peritoneal carcinomatosis, where cancer spreads to the abdominal lining, is a frequent underlying mechanism. Tumor-related inflammation and increased vascular permeability also contribute to fluid accumulation.

Risk Factors

• Advanced-stage cancer, especially with peritoneal involvement.
• Primary tumors of the ovary, pancreas, stomach, or colon.
• Lymphatic obstruction due to tumor growth or treatment effects.
• Prior abdominal surgeries or radiation therapy.
• Underlying liver disease or portal hypertension.

Symptoms

• Abdominal distension and swelling.
• Increased abdominal girth or weight gain.
• Discomfort, pain, or a feeling of fullness.
• Shortness of breath if fluid presses on the diaphragm.
• Nausea, loss of appetite, or early satiety.
• Fatigue or reduced mobility due to discomfort.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging, and laboratory tests. Physical examination may reveal abdominal distension or shifting dullness. Imaging studies, such as ultrasound or CT scans, confirm fluid presence and assess for underlying masses or organ involvement. Paracentesis (fluid aspiration) is performed to analyze the ascitic fluid for cancer cells, protein levels, and other markers. Cytology or biopsy of the fluid or peritoneum may be needed to confirm malignancy.

Treatment Options

Treatment focuses on managing fluid accumulation and addressing the underlying cancer. Options include paracentesis for symptom relief, diuretics (e.g., spironolactone) to reduce fluid retention, and systemic therapies like chemotherapy or targeted treatments to control the primary tumor. In some cases, procedures like peritoneal-venous shunts or intraperitoneal chemotherapy may be considered. Supportive care, including dietary modifications and pain management, is also important.

Prognosis and Follow-Up

Prognosis depends on the type and stage of the underlying cancer, as well as the patient’s overall health. Malignant ascites often indicates advanced disease, and survival outcomes vary. Regular follow-up is essential to monitor fluid recurrence, adjust treatments, and manage symptoms. Imaging and clinical assessments help track disease progression and guide therapeutic decisions.

Complications

• Severe abdominal discomfort or pain.
• Respiratory compromise from diaphragmatic elevation.
• Infection (spontaneous bacterial peritonitis).
• Malnutrition or electrolyte imbalances.
• Reduced quality of life due to physical limitations.

Lifestyle & Prevention

While malignant ascites is primarily cancer-related, maintaining overall health may support treatment tolerance. This includes balanced nutrition, gentle activity, and adherence to prescribed therapies. Preventive measures focus on early cancer detection and management to reduce the risk of advanced disease.

When to Seek Professional Help

Seek medical attention if you experience unexplained abdominal swelling, persistent discomfort, or sudden changes in weight. Prompt evaluation is critical if symptoms worsen or interfere with daily activities, as these may indicate fluid accumulation or disease progression.

Tips for Medical Coders

When coding R18.0 (Malignant ascites), ensure documentation specifies the ascites is cancer-related. Include details about the underlying malignancy, if available, to support the diagnosis. Note whether the condition is a complication of the primary cancer or a separate manifestation. Avoid coding ascites without confirmation of malignancy, as R18.0 is specific to cancer-associated fluid accumulation.